Online citations, reference lists, and bibliographies.
← Back to Search

A Double‐blind, Placebo‐controlled Trial

R. Pinals, S. Kaplan, J. Lawson, B. Hepburn
Published 1986 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Sulfasalazine (SSZ), 3 gm daily, was compared with placebo for treatment of rheumatoid arthritis, in a 15-week randomized, parallel, double-blind trial. Joint tenderness and swelling, morning stiffness, grip strength, and pain score all showed significantly more improvement with SSZ than with placebo. Adverse effects, particularly gastrointestinal reactions, led to withdrawal from the study of 28% of the patients who had been receiving SSZ, but these effects were all readily reversible and not life-threatening. These results confirm previous findings that suppression of rheumatoid synovitis may be induced by SSZ, within 2 months after full maintenance doses are reached.
This paper references
10.1136/ARD.8.3.226
Salazopyrin in the Treatment of Rheumatoid Arthritis
R. Sinclair (1949)
10.1002/ART.1780080214
A Seven‐Day variability study of 499 patients with peripheral rheumatoid arthritis
D. Mainland (1965)
10.1111/J.0954-6820.1968.TB02478.X
Intestinal Clostridium perfringens in rheumatoid arthritis and other collagen diseases.
B. Olhagen (1968)
10.1136/gut.15.12.960
Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease
B. West (1974)
10.2165/00003088-197601060-00002
Clinical Pharmacokinetics of Sulphasalazine
K. Das (1976)
10.1016/S0140-6736(77)90831-5
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
A. Khan (1977)
Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro.
A. Rubinstein (1978)
10.1007/BF01314463
Effects of sulfasalazine on selected lymphocyte subpopulationsin vivo andin vitro
W. Thayer (1979)
10.1136/bmj.280.6212.442
Sulphasalazine in rheumatoid arthritis.
B. McConkey (1980)
10.3109/00365528109182016
Effect of metronidazole and sulfasalazine on the normal human faecal flora.
A. Krook (1981)
10.1172/JCI110474
Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.
W. Stenson (1982)
10.7326/0003-4819-97-5-726
Multiple haematologic abnormalities associated with sulfasalazine.
K. Wheelan (1982)
10.1002/ART.1780241012
Preliminary criteria for clinical remission in rheumatoid arthritis.
R. Pinals (1982)
A biochemical assessment of sulphasalazine in rheumatoid arthritis.
H. Bird (1982)
10.3109/00365528209182073
Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
O. Nielsen (1982)
10.1001/ARCHINTE.1983.00350050056012
Folate status in patients receiving maintenance doses of sulfasalazine.
G. Longstreth (1983)
10.1016/0006-2952(83)90227-7
Inhibition of platelet thromboxane synthetase by sulfasalazine.
W. Stenson (1983)
10.1136/bmj.287.6399.1102
Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.
T. Pullar (1983)
10.1007/BF01296907
Sulfasalazine. Adverse effects and desensitization.
S. Taffet (1983)
10.1136/bmj.287.6399.1099
Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.
V. Neumann (1983)
10.1016/S0025-6196(12)61431-1
Pulmonary infiltrates and eosinophilia associated with sulfasalazine.
K. Wang (1984)
10.7326/0003-4819-101-3-377
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
M. Peppercorn (1984)
10.1136/ard.43.3.398
Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.
K. Grindulis (1984)
Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.
L. Martin (1985)
10.3109/03009748509100404
Does sulphasalazine cause folate deficiency in rheumatoid arthritis?
K. Grindulis (1985)
10.1136/bmj.290.6481.1535
Which component of sulphasalazine is active in rheumatoid arthritis?
T. Pullar (1985)
10.1136/ard.44.12.831
Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
T. Pullar (1985)



This paper is referenced by
10.1038/s41581-021-00430-6
Hypertension-induced cognitive impairment: from pathophysiology to public health
Z. Ungvari (2021)
10.34172/apb.2022.022
Protective Role of Trans-chalcone against the Progression from Simple Steatosis to Non-alcoholic Steatohepatitis: Regulation of miR-122, 21, 34a, and 451
Elham Karimi-Sales (2021)
10.1007/s11356-021-14884-5
Exploring the therapeutic potential of omega-3 fatty acids in depression
Priyanshi Sikka (2021)
10.1038/s41598-021-82032-7
Dexamethasone increased the survival rate in Plasmodium berghei-infected mice
Danilo R. Moreira (2021)
10.3389/fmed.2021.608083
Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
M. Leutner (2021)
10.3389/fcvm.2021.687585
Hydrophilic or Lipophilic Statins?
E. Climent (2021)
10.1080/1744666X.2021.1905523
The use of nasal allergen vs allergen exposure chambers to evaluate allergen immunotherapy
L. Hossenbaccus (2021)
10.1515/sjpain-2021-0038
The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials
Sissel Breivold Roland (2021)
10.1016/j.ijid.2021.02.011
The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010–20
Atieh Darbandi (2021)
10.1038/s41598-021-91923-8
Associations of hypertension burden on subsequent dementia: a population-based cohort study
Hyunjean Jung (2021)
10.1007/s12072-021-10157-y
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Gabriel Tayguara Silveira Guerreiro (2021)
10.20944/PREPRINTS202103.0022.V1
The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis
J. Segal (2021)
10.3389/fpsyt.2021.702617
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Riccardo De Giorgi (2021)
10.1101/2021.06.12.448098
Cysteine dependence in Lactobacillus iners constitutes a novel therapeutic target to modify the vaginal microbiota
S. M. Bloom (2021)
10.3389/fimmu.2021.574425
Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
V. Venditto (2021)
10.3389/fnins.2020.00505
Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson’s Disease: A Cross-Sectional Study
Linyi Li (2020)
10.1007/s12325-020-01232-1
Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis
A. Bignamini (2020)
10.3389/fmed.2020.615858
Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn's Disease: A Systematic Review
Xiaojun Zhuang (2020)
10.3389/fncel.2020.585395
Paradoxical Effects of a Cytokine and an Anticonvulsant Strengthen the Epigenetic/Enzymatic Avenue for Autism Research
D. Béroule (2020)
10.3390/cancers12123671
Pain Management in Childhood Leukemia: Diagnosis and Available Analgesic Treatments
F. Coluzzi (2020)
10.1038/s41598-020-78281-7
The efficacy of probiotics in management of recurrent aphthous stomatitis: a systematic review and meta-analysis
Bin Cheng (2020)
10.1038/s41598-020-77039-5
Eucalyptus oil reduces allergic reactions and suppresses mast cell degranulation by downregulating IgE-FcεRI signalling
Tomoya Nakamura (2020)
Title: Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies. One Sentence Summary: Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry
Kritika Khanna (2020)
10.1136/svn-2020-000364
Vascular protection and regenerative effects of intranasal DL-3-N-butylphthalide treatment after ischaemic stroke in mice
Mengyao Qu (2020)
10.1038/s41598-020-67868-9
Plasma BDNF is a more reliable biomarker than erythrocyte omega-3 index for the omega-3 fatty acid enrichment of brain
D. Sugasini (2020)
10.1186/s12887-020-02336-x
Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital
Majed Al Jeraisy (2020)
10.1113/EP087492
Contemporary stable isotope tracer approaches: Insights into skeletal muscle metabolism in health and disease
M. Brook (2020)
10.1007/s11427-019-1633-3
Brain interstitial fluid drainage and extracellular space affected by inhalational isoflurane: in comparison with intravenous sedative dexmedetomidine and pentobarbital sodium
Guomei Zhao (2020)
10.3390/dairy1030015
Lactic Acid Bacteria: Food Safety and Human Health Applications
Raphael Ayivi (2020)
10.1016/j.abrep.2020.100312
Are non-abstinent reductions in World Health Organization drinking risk level a valid treatment target for alcohol use disorders in adolescents with ADHD?
Henry M. Mitchell (2020)
10.3389/fpsyt.2020.00717
Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment
Katharine Boaden (2020)
10.3389/fimmu.2020.00865
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide
A. Soriano (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar